Mete I Saylan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6662547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	6.3	5,847
3	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
4	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
5	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
6	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	6.3	2,005
7	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, The, 2017, 16, 877-897.	4.9	1,521
8	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 88-106.	4.9	1,512
9	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 389, 1885-1906.	6.3	1,281
10	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health, The, 2022, 7, e105-e125.	4.7	1,199
11	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, The, 2016, 388, 1081-1088.	6.3	1,080
12	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	6.3	890
13	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
14	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
15	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
16	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
17	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	6.3	284
18	EEG phenotype in alcoholism: increased coherence in the depressive subtype. Acta Psychiatrica Scandinavica, 2003, 108, 51-60.	2.2	62

METE I SAYLAN

#	Article	IF	CITATIONS
19	Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12200.	1.8	53
20	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	1.2	44
21	The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 25-37.	1.0	43
22	Global, Regional, and National Levels of Maternal Mortality, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. Obstetrical and Gynecological Survey, 2017, 72, 11-13.	0.2	41
23	Unipolar mania: a distinct disorder?. Journal of Affective Disorders, 2002, 71, 97-103.	2.0	36
24	Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis. Journal of Affective Disorders, 2004, 80, 269-271.	2.0	20
25	Obsessive–Compulsive Disorder Secondary to Bilateral Frontal Damage Due to a Closed Head Injury. Cognitive and Behavioral Neurology, 2004, 17, 118-120.	0.5	14
26	Mother and baby units for schizophrenia. The Cochrane Library, 2007, , CD006333.	1.5	10
27	Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. International Journal of Clinical Practice, 2008, 60, 812-819.	0.8	10
28	Cost of heart failure management in Turkey: results of a Delphi Panel. Anatolian Journal of Cardiology, 2016, 16, 554-562.	0.5	10
29	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 47-61.	1.0	9
30	Olanzapine Versus Chlorpromazine in the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 329-337.	0.7	8
31	Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach. Value in Health Regional Issues, 2013, 2, 171-180.	0.5	8
32	Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study. International Journal of Clinical Practice, 2010, 64, 697-706.	0.8	7
33	Impact of Health Policy Changes on Trends in the Pharmaceutical Market in Turkey. Value in Health Regional Issues, 2016, 10, 48-52.	0.5	6
34	Cost analysis of management of cardiovascular disease comorbidities in Turkey. Journal of Pharmaceutical Health Services Research, 2019, 10, 197-202.	0.3	3
35	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. BMC Medical Informatics and Decision Making, 2021, 21, 241.	1.5	2
36	Analysis of Market Access Agreements in Turkey. Farmeconomia E Percorsi Terapeutici, 2020, 21, .	0.2	0